{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:30:19Z","timestamp":1762353019645,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["843004109"],"award-info":[{"award-number":["843004109"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["11313"],"award-info":[{"award-number":["11313"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Invasive mediastinal nodal staging is recommended by guidelines in selected patients with resectable non-small cell lung cancer (NSCLC). Endosonography is recommended as initial staging technique, followed by confirmatory mediastinoscopy in case of negative N2 or N3 cytology after endosonography. Confirmatory mediastinoscopy however is under debate owing its limited additional diagnostic value, its associated morbidity and its delay in the start of lung cancer treatment. The MEDIASTrial examines whether confirmatory mediastinoscopy can be safely omitted after negative endosonography in mediastinal nodal staging of NSCLC. The present work is the proposed statistical analysis plan of the clinical consequences of omitting mediastinoscopy, which is submitted before closure of the MEDIASTrial and before knowledge of any results was done to enhance transparency of scientific behaviour.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The primary outcome measure of this non-inferiority trial will be unforeseen N2 disease resulting from lobe-specific mediastinal lymph node dissection. For non-inferiority, the upper limit of the 95% confidence interval of the unforeseen N2 rate in the group without mediastinoscopy should not exceed 14.3% in order to probably have no negative impact on survival. Since this is a non-inferiority trial, both an intention to treat (ITT) and a per protocol (PP) analyses will be done. The ITT and the PP analyses should both indicate non-inferiority before the diagnostic strategy omitting mediastinoscopy will be interpreted as non-inferior to the strategy with mediastinoscopy. Secondary outcome measures include 30-day major morbidity and mortality, the total number of days of hospital care, overall and disease free 2-year survival, generic and disease-specific health related quality of life and cost-effectiveness and cost-utility of staging strategies with and without mediastinoscopy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The MEDIASTrial will determine if confirmatory mediastinoscopy can be omitted after tumour negative systematic endosonography in invasive mediastinal staging of patients with resectable NSCLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>Netherlands Trial Register<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.trialregister.nl\/trial\/6344\">NL6344\/NTR6528<\/jats:ext-link>. Registered on 2017 July 06<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13063-021-05127-6","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T10:03:36Z","timestamp":1614420216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): a statistical analysis plan"],"prefix":"10.1186","volume":"22","author":[{"name":"on behalf of the MEDIASTrial study group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelle E.","family":"Bousema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jouke T.","family":"Annema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik H. F. M.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ad F. T. M.","family":"Verhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel G. W.","family":"Dijkgraaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4828-5725","authenticated-orcid":false,"given":"Frank J. C.","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"issue":"6","key":"5127_CR1","first-page":"546","volume":"47","author":"P Vilmann","year":"2015","unstructured":"Vilmann P, Clementsen PF, Colella S, Siemsen M, de Leyn P, Dumonceau J, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy. 2015;47(6):546\u201360.","journal-title":"Endoscopy"},{"issue":"5","key":"5127_CR2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/ejcts\/ezu028","volume":"45","author":"P De Leyn","year":"2014","unstructured":"De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45(5):787\u201398.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"20","key":"5127_CR3","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1001\/jama.2010.1705","volume":"304","author":"JT Annema","year":"2010","unstructured":"Annema JT, van Meerbeeck JP, Rintoul RC, Dooms C, Deschepper E, Dekkers OM, et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA. 2010;304(20):2245\u201352.","journal-title":"JAMA"},{"issue":"6","key":"5127_CR4","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jtho.2019.02.032","volume":"14","author":"JE Bousema","year":"2019","unstructured":"Bousema JE, van Dorp M, Noyez VJJM, Dijkgraaf MGW, Annema JT, van den Broek FJC. Unforeseen N2 disease after negative endosonography findings with or without confirmatory mediastinoscopy in resectable non\u2013small cell lung cancer: a systematic review and meta-analysis. J Thorac Oncol. 2019;14(6):979\u201392.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"5127_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12893-018-0359-6","volume":"18","author":"JE Bousema","year":"2018","unstructured":"Bousema JE, Dijkgraaf MGW, Papen-Botterhuis NE, Schreurs HW, Maessen JG, van der Heijden EH, et al. MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): study protocol of a multicenter randomised controlled trial. BMC Surg. 2018;18(1):27.","journal-title":"BMC Surg"},{"key":"5127_CR6","unstructured":"Stichting Palga. Landelijke PALGA Protocol: longcarcinoom (resectie). 2019; Available at: https:\/\/www.palga.nl\/assets\/uploads\/Protocollen\/Longcarcinoom.pdf."},{"issue":"23","key":"5127_CR7","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/jama.2017.18556","volume":"318","author":"C Gamble","year":"2017","unstructured":"Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dor\u00e9 C, et al. Guidelines for the content of statistical analysis plans in clinical trials. JAMA. 2017;318(23):2337\u201343.","journal-title":"JAMA"},{"issue":"19","key":"5127_CR8","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.2832","volume":"26","author":"I Campbell","year":"2007","unstructured":"Campbell I. Chi-squared and Fisher\u2013Irwin tests of two-by-two tables with small sample recommendations. Stat Med. 2007;26(19):3661\u201375.","journal-title":"Stat Med"},{"issue":"8","key":"5127_CR9","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/sim.6808","volume":"35","author":"FMTA Busing","year":"2016","unstructured":"Busing FMTA, Weaver B, Dubois S. 2 \u00d7 2 tables: a note on Campbell\u2019s recommendation. Stat Med. 2016;35(8):1354\u20138.","journal-title":"Stat Med"},{"issue":"8","key":"5127_CR10","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17(8):873.","journal-title":"Stat Med"},{"issue":"1","key":"5127_CR11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57(1):289.","journal-title":"J R Stat Soc Ser B Methodol"},{"issue":"8","key":"5127_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2010.03.004","volume":"63","author":"D Moher","year":"2010","unstructured":"Moher D, Hopewell S, Schulz KF, Montori V, G\u00f8tzsche PC, Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63(8):e1\u2013e37.","journal-title":"J Clin Epidemiol"},{"issue":"14","key":"5127_CR13","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1056\/NEJMra1510063","volume":"377","author":"L Mauri","year":"2017","unstructured":"Mauri L, D\u2019Agostino RB. Challenges in the design and interpretation of noninferiority trials. N Engl J Med. 2017;377(14):1357\u201367.","journal-title":"N Engl J Med"},{"issue":"3","key":"5127_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar Behav Res"},{"issue":"10","key":"5127_CR15","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jama.2016.10349","volume":"316","author":"JC Kuijvenhoven","year":"2016","unstructured":"Kuijvenhoven JC, Korevaar DA, Tournoy KG, Malfait TLA, Dooms C, Rintoul RC, et al. Five-year survival after endosonography vs mediastinoscopy for mediastinal nodal staging of lung cancer. JAMA. 2016;316(10):1110\u20132.","journal-title":"JAMA"},{"issue":"2","key":"5127_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien P. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05127-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-021-05127-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05127-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T23:45:14Z","timestamp":1724543114000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05127-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5127"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05127-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2021,2,27]]},"assertion":[{"value":"16 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The medical ethical committee of the Maxima Medical Centre has approved the study protocol and all participating centres (MEC number W17.063) on June, 15th, 2017. All participating centres signed the research contract prior to start inclusion. Before randomisation, written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Bousema and Dr. van den Broek report grants from ZonMw and the Dutch Cancer Society, during the conduct of this study. Prof. Dr. Dijkgraaf and Prof. Dr. Verhagen have nothing to disclose. Dr. van der Heijden reports research grants from Pentax Medical, Philips Medical, unrelated to the content of this study. Consultancy for Philips-Volcano, Pentax Medical. Prof. Dr. Annema reports non-financial support from Hitachi Medical systems, non-financial support from Pentax, grants from Cook medical, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}